RNXT RenovoRx, Inc.
Price Chart
Executive Summary
RenovoRx announced management participation in an AGP healthcare showcase and highlighted record Q1 2026 RenovoCath revenue of $563K, missing consensus estimates of $654K. The company also provided an update on its Phase III TIGeR-PaC trial expecting full enrollment by June 2026 and final data in mid-2027. The filing is primarily a routine investor relations event with a modest revenue miss.
Actionable Insight
Monitor for trial enrollment completion in June 2026 and the eventual top-line data readout in mid-2027. The revenue miss is non-material for a clinical-stage biotech.
Key Facts
- Record Q1 2026 RenovoCath revenue of $563,000, missing consensus of $654,000
- Expected notification of full enrollment in Phase III TIGeR-PaC trial in early June 2026
- Management to present at AGP Annual Healthcare Company Showcase on May 20, 2026
Financial Impact
Revenue miss of approximately $91,000 (13.9%) against consensus
Risk Factors
- Clinical trial failure or delay
- Cash burn and need for additional financing
- Low liquidity and market cap vulnerability
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
19d ago
|
Press Release
| $0.9160 $0.9210 | ▲ +0.55% | ▼ −0.54% | $0.8440 (−7.86%) |
|
May 19, 2026
26d ago
|
Press Release
| $0.8060 $0.9052 | ▲ +12.31% | ▲ +10.06% | $0.8440 (+4.71%) |
|
May 15, 2026
4w ago
|
10-K/A
| $0.7830 $0.9160 | ▲ +16.99% | ▲ +15.37% | $0.8440 (+7.79%) |
|
May 14, 2026
4w ago
|
8-K
| $0.8200 $0.8820 | ▲ +7.56% | ▲ +6.60% | $0.8440 (+2.93%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $0.8310 $0.9280 | ▲ +11.67% | ▲ +8.56% | $0.8440 (+1.56%) |
|
Apr 28, 2026
6w ago
|
EFFECT
| $0.8400 $0.9280 | ▲ +10.48% | ▲ +8.78% | $0.8440 (+0.48%) |
|
Apr 16, 2026
8w ago
|
S-3
| $1.00 $0.8570 | ▼ −14.30% | ▼ −14.85% | $0.8440 (−15.60%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.03 $0.9490 | ▼ −7.86% | ▼ −9.26% | $0.8440 (−18.06%) |
|
Mar 30, 2026
10w ago
|
8-K
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access